Mirum Posts $1.06 Q2 Loss Per Share, Widening from Prior Year
Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment
Negative
Importance
7
Price
$97.54
Mkt Cap
$6.451B
52W Low
$50.25
52W High
$130
52W Position
94% above low
Off High
25% below high
Rel. Volume
0.8× avg
Market data snapshot near publication time
MIRM sits 94% above its 52-week low of $50.25.
Summary
Mirum reported a Q2 loss of $1.06 per share, a significant widening from the prior year's loss. This follows a Q1 net loss of $790.2 million driven by the Bluejay acquisition charge, and the recent $690 million convertible note offering. The loss underscores ongoing cash burn and integration costs. No revenue or guidance figures were provided in the headline.
At the time of this announcement, MIRM was trading at $97.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $50.25 to $130.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.
Price Chart
MIRM - Latest Insights
MIRM
May 18, 2026, 4:06 PM EDT
Price at Filing:
$95.49
Real-time Price:
$100.65
Change:
+$5.16 (+5%)
Market Cap:
$6.535B
MIRM
May 13, 2026, 12:17 AM EDT
Price at Filing:
$104.50
Real-time Price:
$100.65
Change:
-$3.85 (-4%)
Market Cap:
$6.535B
MIRM
May 12, 2026, 5:17 PM EDT
Price at Filing:
$104.50
Real-time Price:
$100.65
Change:
-$3.85 (-4%)
Market Cap:
$6.535B
MIRM
May 06, 2026, 4:07 PM EDT
Price at Filing:
$110.00
Real-time Price:
$100.65
Change:
-$9.35 (-8%)
Market Cap:
$6.535B
MIRM
May 06, 2026, 4:04 PM EDT
Price at Filing:
$110.00
Real-time Price:
$100.65
Change:
-$9.35 (-8%)
Market Cap:
$6.535B